If We Can Do It for Misoprostol, Why Not for Mifepristone? The Case for Taking Mifepristone Out of the Office in Medical Abortion

Contraception; 2015 Sep; 92(3):194-6; doi:10.1016/j.contraception.2015.06.011. Published: June 17, 2015.

Given the highly political nature of abortion in the United States, the provision of medical abortion with mifepristone and misoprostol has always occurred under a unique set of circumstances and restrictions. The current FDA-approved medical abortion regimen requires clinicians to administer mifepristone in the office, and requires women to return to the office for the misoprostol. Six studies, enrolling over 1800 women, found that the option of taking mifepristone out of the office was popular and acceptable among women and providers.